BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 27158757)

  • 1. Comprehensive Immunohistochemical Study of Programmed Cell Death Ligand 1 (PD-L1): Analysis in 5536 Cases Revealed Consistent Expression in Trophoblastic Tumors.
    Inaguma S; Wang Z; Lasota J; Sarlomo-Rikala M; McCue PA; Ikeda H; Miettinen M
    Am J Surg Pathol; 2016 Aug; 40(8):1133-42. PubMed ID: 27158757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of PD-L1 expression in trophoblastic tissues and tumors.
    Lu B; Teng X; Fu G; Bao L; Tang J; Shi H; Lu W; Lu Y
    Hum Pathol; 2019 Feb; 84():202-212. PubMed ID: 30339966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases.
    Veras E; Kurman RJ; Wang TL; Shih IM
    Int J Gynecol Pathol; 2017 Mar; 36(2):146-153. PubMed ID: 27362903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of neural cell adhesion molecule L1 (CD171) in neuroectodermal and other tumors: An immunohistochemical study of 5155 tumors and critical evaluation of CD171 prognostic value in gastrointestinal stromal tumors.
    Inaguma S; Wang Z; Lasota JP; Miettinen MM
    Oncotarget; 2016 Aug; 7(34):55276-55289. PubMed ID: 27419370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
    Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
    Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors.
    Sloan EA; Ring KL; Willis BC; Modesitt SC; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):326-333. PubMed ID: 27984238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Analytical Comparison of Dako 28-8 PharmDx Assay and an E1L3N Laboratory-Developed Test in the Immunohistochemical Detection of Programmed Death-Ligand 1.
    Cogswell J; Inzunza HD; Wu Q; Feder JN; Mintier G; Novotny J; Cardona DM
    Mol Diagn Ther; 2017 Feb; 21(1):85-93. PubMed ID: 27667773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed cell death ligand-1 (PD-L1) expression in extrahepatic biliary tract cancers: a comparative study using 22C3, SP263 and E1L3N anti-PD-L1 antibodies.
    Ahn S; Lee Y; Kim JW; Lee JC; Hwang JH; Yoon YS; Cho JY; Han HS; Choi Y; Kim H
    Histopathology; 2019 Oct; 75(4):526-536. PubMed ID: 31081949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
    Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
    Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association Between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma.
    Kim HS; Lee JY; Lim SH; Park K; Sun JM; Ko YH; Baek CH; Son YI; Jeong HS; Ahn YC; Lee MY; Hong M; Ahn MJ
    Cancer Res Treat; 2016 Apr; 48(2):527-36. PubMed ID: 26511814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1, B7-H3 and VISTA are highly expressed in gestational trophoblastic neoplasia.
    Zong L; Zhang M; Wang W; Wan X; Yang J; Xiang Y
    Histopathology; 2019 Sep; 75(3):421-430. PubMed ID: 31013360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death Ligand 1 (PD-L1) Expression in Malignant Mesenchymal Tumors.
    Kösemehmetoğlu K; Özoğul E; Babaoğlu B; Tezel GG; Gedikoğlu G
    Turk Patoloji Derg; 2017; 1(1):192-197. PubMed ID: 28832074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-checkpoint status in penile squamous cell carcinoma: a North American cohort.
    Cocks M; Taheri D; Ball MW; Bezerra SM; Del Carmen Rodriguez M; Ricardo BFP; Bivalacqua TJ; Sharma RB; Meeker A; Chaux A; Burnett AL; Netto GJ
    Hum Pathol; 2017 Jan; 59():55-61. PubMed ID: 27663086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
    Chowdhury S; Veyhl J; Jessa F; Polyakova O; Alenzi A; MacMillan C; Ralhan R; Walfish PG
    Oncotarget; 2016 May; 7(22):32318-28. PubMed ID: 27086918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung.
    Kim S; Koh J; Kim MY; Kwon D; Go H; Kim YA; Jeon YK; Chung DH
    Hum Pathol; 2016 Dec; 58():7-14. PubMed ID: 27473266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas.
    Kir G; Soylemez T; Olgun ZC; Aydin A; McCluggage WG
    Virchows Arch; 2020 Dec; 477(6):845-856. PubMed ID: 32594230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28-8 and E1L3N).
    Ma J; Li J; Qian M; Han W; Tian M; Li Z; Wang Z; He S; Wu K
    Diagn Pathol; 2018 Nov; 13(1):91. PubMed ID: 30463584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
    Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
    Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.